LaserBond Limited (LSRBF) Fair Value & Analysis
Industrials · US · Market cap $53.2M
Fair value as of: Jun 24, 2026
Analysis
LaserBond Limited (LSRBF) currently trades at $0.4500, while our model-based Fair Value estimate is $0.4200 — implying the stock looks roughly 6.7% overvalued today. We read business quality at 85/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
LaserBond Limited, a surface engineering company, engages in the development and application of materials, technologies, and methodologies to enhance operating performance and wear life of capital-intensive machinery components in Australia. It operates through Products, Services, Technology, and Research and Development segments. The company offers composite carbide steel mill rolls. It also provides laser cladding, thermal spraying, welding, machining, heat treatment, and remanufacturing, as well as metallurgy lab and surface coatings. In addition, the company licenses its surface engineering technologies. It serves mining, drilling, mineral processing, power generation, transport and marine, plant and machinery, manufacturing, fluid handling, and agriculture industries. The company was incorporated in 1992 and is headquartered in Sydney, Australia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is LaserBond Limited (LSRBF) undervalued?
What is the fair value of LSRBF?
What is the quality score of LSRBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.